Search results
Results From The WOW.Com Content Network
Many investors define successful investing as beating the market average over the long term. But the risk of stock...
For premium support please call: 800-290-4726 more ways to reach us
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Join us as we cover personal finance, investing, business news, and global economic trends. Learn how to budget, save money on your TV watching, or find apps to help with managing your finances and growing your wealth. Get breaking Business News and the latest corporate happenings from AOL.
For premium support please call: 800-290-4726 more ways to reach us
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
Across the first two days of August, the S&P 500 ( ^GSPC) slid 3.2% while the Nasdaq Composite ( ^IXIC) sank 4.7%. The moves extended a previous drawdown in the Nasdaq, with the index entering a ...
For premium support please call: 800-290-4726 more ways to reach us